Loading
Chronic Lymphocytic Leukemia / mRNA COVID-19 Vaccine / Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 2 registry record describing a planned comparison of GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine) versus standard-of-care COVID-19 vaccine in patients with chronic lymphocytic leukemia. The registry record contains no posted results, outcome data, or efficacy findings; it describes only the study design, primary endpoint (T cell response at day 56), and enrollment status (47 participants enrolled).
Phase 2, Interventional, Randomized, Parallel, Triple masking, Prevention purpose. Chronic Lymphocytic Leukemia, COVID-19 Infection; age from 18 Years. Intervention: Arm I (GEO-CM04S1). Compared with: Arm II (mRNA Covid-19 Vaccine) — Active Comparator. n = 47. 1 site: United States.
This is a completed Phase 2 registry record describing a planned comparison of GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine) versus standard-of-care COVID-19 vaccine in patients with chronic lymphocytic leukemia. The registry record contains no posted results, outcome data, or efficacy findings; it describes only the study design, primary endpoint (T cell response at day 56), and enrollment status (47 participants enrolled).
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
No clinical impact can be assessed from this registry record alone, as no results are reported. Clinicians should await publication of trial results to evaluate efficacy and immunogenicity of GEO-CM04S1 in this immunocompromised population.
Phase 2 trial in a vulnerable population with immunosuppression; registry record reports no results, only planned design and enrollment completion.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record alone, as no results are reported. Clinicians should await publication of trial results to evaluate efficacy and immunogenicity of GEO-CM04S1 in this immunocompromised population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05672355). This is a study registration, not published results. Lead sponsor: City of Hope Medical Center. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 47 participants (ACTUAL). Conditions: Chronic Lymphocytic Leukemia, COVID-19 Infection. Interventions: PROCEDURE: Biospecimen Collection; BIOLOGICAL: mRNA COVID-19 Vaccine; BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1. Primary outcome measures: T cell response , Baseline to day 56. Brief summary: This phase II trial compares the effect of the GEO-CM04S1 vaccine with the current standard of care vaccine in preventing COVID-19 infections in patients with chronic lymphocytic leukemia (CLL). The GEO-CM04S1 vaccine uses a modified vaccinia virus (MVA) backbone that may be more effective at boosting COVID-19 immunity in patients with poor immune responses. MVA strongly induces T cell expansion (infection fighting blood cells) even in the background of a suppressed immune system, which is the case in the targeted CLL patient population. Using the GEO-CM04S1 vaccine may be more effective at preventing COVID-19 infection in patients diagnosed with CLL.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.